ALX3

Across TCGA pan-cancer cohorts, ALX3 RNA differs between tumor and matched normal tissue in 7 of 18 cancer types tested, making tumor–normal expression one of ALX3’s most consistent transcriptional readouts.

The strongest signal is observed in lung squamous cell carcinoma (LUSC), where ALX3 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types ALX3 is over-expressed in tumor, although a few such as PRAD and KIRC show the opposite, repressed pattern.

LUSC, LUAD, and LIHC are the cancer types where ALX3 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in ALX3 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
LUSC	All	All	+0.445	<.001	6	view →
LUAD	All	All	+0.343	<.001	5	view →
LIHC	All	All	+0.305	.005	3	view →
UCEC	All	IV	+1.560	<.001	2	view →
PRAD	All	All	−0.045	<.001	2	view →
KIRC	All	All	−0.010	.016	2	view →
BRCA	All	II,III,IV	+0.097	.036	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 7 strongest of 7 lineages.

ALX3–LUSC

Open the LUSC breakdown →